This HTML5 document contains 76 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n9http://linked.opendata.cz/resource/drugbank/drug/DB06770/identifier/chebi/
foafhttp://xmlns.com/foaf/0.1/
n13http://linked.opendata.cz/resource/drugbank/drug/DB06770/identifier/wikipedia/
n15http://linked.opendata.cz/resource/drugbank/dosage/
n11http://www.rxlist.com/
n17http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n8http://linked.opendata.cz/resource/drugbank/drug/DB06770/identifier/kegg-drug/
n7http://linked.opendata.cz/resource/drugbank/drug/DB06770/identifier/drugbank/
n5http://linked.opendata.cz/resource/drugbank/patent/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n12http://linked.opendata.cz/resource/drugbank/drug/DB06770/identifier/national-drug-code-directory/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#

Statements

Subject Item
n2:DB06770
rdf:type
n3:Drug
n3:dosage
n15:271B539F-363D-11E5-9242-09173F13E4C5 n15:271B53A0-363D-11E5-9242-09173F13E4C5 n15:271B53A1-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# Taylor PM, Chengelis CP, Miller WR, Parker GA, Gleason TR, Cozzi E: Evaluation of propofol containing 2% benzyl alcohol preservative in cats. J Feline Med Surg. 2012 Aug;14(8):516-26. doi: 10.1177/1098612X12440354. Epub 2012 Feb 24. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/22366290 # Novak E, Stubbs SS, Sanborn EC, Eustice RM: The tolerance and safety of intravenously administered benzyl alcohol in methylprednisolone sodium succinate formulations in normal human subjects. Toxicol Appl Pharmacol. 1972 Sep;23(1):54-61. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/4560999 # Meinking TL, Villar ME, Vicaria M, Eyerdam DH, Paquet D, Mertz-Rivera K, Rivera HF, Hiriart J, Reyna S: The clinical trials supporting benzyl alcohol lotion 5% (Ulesfia): a safe and effective topical treatment for head lice (pediculosis humanus capitis). Pediatr Dermatol. 2010 Jan-Feb;27(1):19-24. doi: 10.1111/j.1525-1470.2009.01059.x. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/ 20199404
n3:group
approved
n3:indication
Ulesfia (benzyl alcohol) lotion is indicated for the topical treatment of head lice infestation in patients 6 months of age and older. Ulesfia Lotion does not have ovicidal activity.
owl:sameAs
n17:DB06770
dcterms:title
Benzyl alcohol
adms:identifier
n7:DB06770 n8:D00077 n9:17987 n12:59630-780-08 n13:Benzyl_alcohol
n3:mechanismOfAction
Benzyl alcohol inhibits lice from closing their respiratory spiracles, allowing the vehicle to obstruct the spiracles and causing the lice to asphyxiate.
n3:patent
n5:6793931 n5:5858383 n5:6139859 n5:7294342
n3:synonym
alpha-Toluenol Benzyl alcohol (Hydroxymethyl)benzene Benzalcohol Hydroxymethylbenzene Phenylmethyl alcohol Benzenecarbinol Aromatic alcohol Bentalol Alcoholum benzylicum Alcoolbenzylique Benzalalcohol alpha-Hydroxytoluene Benzylalkohol Benzoyl alcohol Benzenemethanol Phenylmethanol Benzylic alcohol Phenylcarbinol Alcool benzylique
n3:toxicity
1250 mg/kg (rat, oral) LD50 400 mg/kg IPR-RAT LD50 2000 mg/kg SKN-RBT LD50 53 mg/kg IVN-RAT LD50 2500 mg/kg ORL-GPG LD50
n3:synthesisReference
Cornelis Jongsma, Leon H. B. Frijns, Paula A. M. Raven-Donners, "Method for the preparation of a pure alkali metal benzoate and benzyl alcohol." U.S. Patent US4296245, issued June, 1940.
foaf:page
n11:ulesfia-drug.htm
n3:IUPAC-Name
n4:271B53A6-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B53AC-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B53AB-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B53A8-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B53A9-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B53AA-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B53A4-363D-11E5-9242-09173F13E4C5 n4:271B53BC-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B53BF-363D-11E5-9242-09173F13E4C5 n4:271B53A2-363D-11E5-9242-09173F13E4C5 n4:271B53A5-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B53A3-363D-11E5-9242-09173F13E4C5
n3:pKa
n4:271B53C0-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B53B2-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B53B3-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B53AD-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B53AE-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B53B0-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B53AF-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B53B1-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Head lice
n3:casRegistryNumber
100-51-6
n3:category
n3:Bioavailability
n4:271B53B8-363D-11E5-9242-09173F13E4C5
n3:Boiling-Point
n4:271B53BE-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B53BA-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B53BB-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B53BD-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B53B7-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B53B6-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B53B9-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B53A7-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B53B4-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B53B5-363D-11E5-9242-09173F13E4C5